Sentrimed

Sentrimed is a private, clinical-stage biotechnology company developing targeted oncology therapies based on cell-to-cell communication biology. The company is focused on "contact normalization," a scientific framework aimed at restoring the body's ability to recognize, contain, and eliminate abnormal cells, with an initial emphasis on cancers driven by podoplanin (PDPN). Its lead program, MASL, is an orally dosed bioactive therapeutic derived from Maackia amurensis seed lectin that inhibits PDPN signaling and is being studied in a Phase 1 trial in oral cancer. Sentrimed positions MASL as a biomarker-driven, potentially well-tolerated therapy for aggressive cancers and potentially malignant disorders with significant unmet need. The company's technology appears to be licensed from Rowan University and has been supported by NIH/STTR funding.